Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Trikafta, a triple combination therapy for CF in patients with specific gene mutations, reaches endpoint in Phase III clinical trial The crisis of purchasing imported consumables in bulk in 10 provinc ...

Aero flavours list️ In 2019, more than 10,000 cases were investigated and dealt with. Past stories of drug counterfeiting that were not shown on ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Drug-resistant infections are most prevalent in critical care units Antibiotics are hailed as medical saviours. But they are increasingly facing a crafty adversary: bacteria that mutate and adapt ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...